COMUNICADO: Announcing a New Era in Alzheimer's (y 2)

Actualizado 30/10/2012 17:47:04 CET


1) Wischik CM, Bentham P, Wischik DJ, Seng KM. Tau aggregation inhibitor
(TAI) therapy with rember[TM] arrests disease progression in mild and moderate
Alzheimer's disease over 50 weeks. Alzheimer's and Dementia 2008;4:T167. Abstract
available at: http://www.alzheimersanddementia.com/article/S1552-5260(08)00598-0/fulltext
. Accessed October 2012.
2) ClinicalTrials.gov. Safety and efficacy study evaluating TRx0237 in subjects
with mild to moderate Alzheimer's disease. Available at:
http://www.clinicaltrials.gov/ct2/show/NCT01689246. Accessed October 2012.
3) ClinicalTrials.gov. Safety and efficacy study evaluating TRx0237 in subjects
with mild Alzheimer's disease. Available at:
http://www.clinicaltrials.gov/ct2/show/NCT01689233. Accessed October 2012.
4) Wischik CM, Edwards PC, Lai RYK, Roth M, Harrington CR. Selective inhibition
of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA
1996;93:11213-11218. Full article available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC38310. Accessed October 2012.
5) Wischik CM, Lai RYK, Harrington CR. Modelling prion-like processing of tau
protein in Alzheimer's disease for pharmaceutical development. In: Brain
MicrotubuleAssociated Proteins: Modifications in Disease, eds. Avila J, Brandt R,
Kosik KS. (1997) pp. 185-241. Amsterdam: Harwood Academic Publishers.
6) Wischik CM, Wischik DJ, Storey JMD, Harrington CR. Rationale for
tau-aggregation inhibitor therapy in Alzheimer's disease and other tauopathies. In:
Emerging Drugs and Targets for Alzheimer's Disease. Volume 1: Beta-Amyloid, Tau
Protein and Glucose Metabolism, ed. Martinez A. (2010) pp. 210-232. Cambridge: RSC
Publishing.
7) Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, et al.
Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols,
and porphyrins. J Biol Chem 2005;280:7614-7623. Full article available at:
http://www.jbc.org/content/280/9/7614.long. Accessed October 2012.
8) Alzheimer A. On a peculiar disease of the cerebral cortex. Allgemeine
Zeitschrift fuer Psychiatrie und Psychisch-Geritlich Medicin 1907;64:146-148.
9) World Health Organization News Release. Dementia cases set to triple by 2050
but still largely ignored. Available at:
http://www.who.int/mediacentre/news/releases/2012/dementia_20120411/en/index.html.
Accessed October 2012.
10) Mukaetova-Ladinska EB, Garcia-Sierra F, Hurt J, Gertz HJ, Xuereb JH, Hills
R, et al. Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals
biphasic synaptic protein response during progression of Alzheimer's disease. Am J
Pathol 2000;157:623-636. Full article available at:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1850134. Accessed October 2012.
11) Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes.
Acta Neuropathol 1991;82:239-259. Abstract available at:
http://www.ncbi.nlm.nih.gov/pubmed/1759558. Accessed October 2012.
12) Soto C. Transmissible proteins: expanding the prion heresy. Cell 2012;
149:968-977. Full article available at:
http://www.sciencedirect.com/science/article/pii/S0092867412005818. Accessed
October 2012.

CONTACT: For press enquiries please contact: U.S. media contacts:Liz Moench +1-610-659-5093; Courtney Hollinger +1-484-674 6800; Outside theU.S. media contacts: Richard Anderson +44(0)7973-950376, Email:press@taurx.com

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación

Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies